Literature DB >> 3393230

Effect of chronic deuterated and non-deuterated phenelzine on rat brain monoamines and monoamine oxidase.

L E Dyck1, A V Juorio, D A Durden, A A Boulton.   

Abstract

The effects of phenelzine and 1,1-dideuterophenelzine (0.5 or 2.5 mg/kg/day) administered s.c. via miniosmotic pumps for 13 days were compared. Striatal levels of p-tryrosine and tryptophan were unaffected by either treatment. The concentrations of DOPAC, HVA and 5-HIAA were dose-dependently decreased by phenelzine and deuterated phenelzine; furthermore, the deuterated compound decreased the amounts of these acids more than the same dose of phenelzine. Dopamine levels were increased by a rather small amount by all drug treatments; no effects of drug dose or drug type (deuterated or nondeuterated) were observed. With the exception of phenylethylamine, qualitatively similar effects were found with all other amines measured; their amounts were increased dose-dependently and the effects of deuterated phenelzine were greater than those of phenelzine. Rat cerebral MAO activity was inhibited dose-dependently by phenelzine and by deuterated phenelzine. Type A MAO was inhibited more than type B, and deuterated phenelzine inhibited both types more than did phenelzine. The present study shows that the efficacy of phenelzine was increased about 5-fold by deuteration, that deuterated phenelzine increased tryptamine, m-tyramine and p-tyramine levels much more than it did the other monoamines, that phenylethylamine levels were least affected by the drug treatments, and that deuterated phenelzine inhibited MAO more than did phenelzine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393230     DOI: 10.1007/bf00168839

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Involvement of brain trace amines in the behavioural effects of phenelzine.

Authors:  K M Dewar; L E Dyck; D A Durden; A A Boulton
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

2.  Microassay for the estimation of monoamine oxidase activity.

Authors:  P H Wu; L E Dyck
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system.

Authors:  P Blier; C De Montigny; A J Azzaro
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

4.  Effect of deuterium substitution on the penetration of beta-phenylethylhydrazine into the rat brain.

Authors:  K M Dewar; L E Dyck; D A Durden; A A Boulton
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

5.  The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irreversible inhibitor of monoamine oxidase--II. Studies in vivo.

Authors:  B V Clineschmidt; A Horita
Journal:  Biochem Pharmacol       Date:  1969-05       Impact factor: 5.858

6.  The regulation of noradrenaline synthesis in central nerve terminals by autoreceptors and heteroreceptors in rat.

Authors:  P J Birch; M Fillenz
Journal:  Neurosci Lett       Date:  1985-08-30       Impact factor: 3.046

Review 7.  CNS dopamine autoreceptors: distribution, pharmacology, and function.

Authors:  R H Roth
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

8.  Substrate selectivity of type A and type B monoamine oxidase in rat brain.

Authors:  H Kinemuchi; Y Wakui; K Kamijo
Journal:  J Neurochem       Date:  1980-07       Impact factor: 5.372

9.  Deuterium isotope effects on the enzymatic oxidative deamination of trace amines.

Authors:  P H Yu; S Barclay; B Davis; A A Boulton
Journal:  Biochem Pharmacol       Date:  1981-11-15       Impact factor: 5.858

10.  Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration.

Authors:  R P Kwok; A V Juorio
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.